The role of constitutively activated STAT3 in B16 melanoma cells.
Constitutively activated STAT3 is found frequently in a wide variety of human tumors, including melanoma. Moreover, constitutive STAT3 activation actively participates in tumor formation and progression, making STAT3 an attractive target for cancer therapy. We report here that in murine B16 melanoma cells, which have been previously shown to express constitutively active STAT3, the expression of a mutant form of STAT3 with the canonical tyrosine phosphorylation site (residue 705) mutated to phenylanaine has dominant-negative properties (STAT3-DN). STAT3-DN inhibits STAT3 tyrosine phosphorylation and STAT3-dependent DNA binding activity. Most importantly, STAT3-DN expression in B16 cells inhibits their invasiveness, as well as their melanogenesis by down-regulation of tyrosinase mRNA and protein expression as well as tyrosinase activity. These results suggest that STAT3 signaling plays a critical role in regulating melanoma behavior, and may represent a druggable target for melanoma therapy.
Yang
Chuan He
CH
Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center and the Center for Cancer Research, Memphis, TN, USA.
Fan
Meiyun
M
Slominski
Andrzej T
AT
Yue
Junming
J
Pfeffer
Lawrence M
LM
J Biol Chem. 1996 Apr 5;271(14):8057-61
8626489
Curr Opin Cell Biol. 2001 Apr;13(2):211-7
11248555
Cell Mol Life Sci. 1999 Sep;55(12):1559-67
10526573
Mol Cell Biol. 1998 May;18(5):2553-8
9566875
Oncogene. 2000 May 15;19(21):2474-88
10851046
Science. 1995 Jul 7;269(5220):81-3
7541555
Immunity. 1999 Jan;10(1):105-15
10023775
Oncogene. 2000 May 15;19(21):2607-11
10851059
J Investig Dermatol Symp Proc. 1999 Sep;4(1):24-8
10537003
Science. 1997 May 30;276(5317):1418-20
9162009
Blood. 2001 May 1;97(9):2846-53
11313280
Cancer. 2002 Oct 15;95(8):1663-72
12365014
Oncogene. 2000 Dec 27;19(56):6613-26
11426647
J Cell Sci. 1988 Mar;89 ( Pt 3):287-96
3143738
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4
9108058
Cell. 1994 Apr 8;77(1):63-71
7512451
J Clin Invest. 1998 Oct 1;102(7):1385-92
9769331
Oncogene. 2002 Oct 10;21(46):7001-10
12370822
J Biol Chem. 1996 May 31;271(22):13221-7
8675499
Physiol Rev. 2004 Oct;84(4):1155-228
15383650
Mol Cell Biol. 1996 Apr;16(4):1595-603
8657134
J Biomed Sci. 1998;5(2):79-85
9662066
Cancer Res. 1999 Oct 15;59(20):5059-63
10537273
Science. 1994 Apr 1;264(5155):95-8
8140422
Oncogene. 2005 Aug 25;24(36):5552-60
16007214
Am J Physiol Cell Physiol. 2000 Feb;278(2):C331-5
10666028
Cancer Res. 1991 Nov 1;51(21):5881-7
1718587
J Biol Chem. 2002 Apr 26;277(17):15132-41
11830592
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9097-101
7568080
Anticancer Res. 1998 Sep-Oct;18(5B):3709-15
9854482
Oncogene. 2000 May 15;19(21):2496-504
10851048
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5568-72
9576923
Oncogene. 2000 May 15;19(21):2577-84
10851056
Oncogene. 2000 May 15;19(21):2557-65
10851054
J Clin Invest. 2001 Feb;107(3):351-62
11160159
Histopathology. 2000 May;36(5):387-402
10792480